Axsome Therapeutics Inc AXS-12 CONCERT Results Call Transcript
Good morning, ladies and gentlemen, and welcome to Axsome Therapeutics Conference Call. (Operator Instruction] As a reminder, today's conference call is being recorded.
I would now like to turn the conference over to your host, Mr. Mark Jacobson, Senior Vice President of Operations at Axsome Therapeutics. Please go ahead.
Thank you, operator. Good morning, everyone, and thank you for joining us on today's conference call to discuss the positive top line results from the CONCERT Phase II trial of AXS-12 in patients with narcolepsy. A press release announcing that AXS-12 achieved a primary endpoint in the trial crossed the wire a short time ago, and is available on our website at axsome.com.
During today's call, we will be making certain forward-looking statements. These statements may include statements regarding, among other things, the efficacy, safety and the intended utilization of investigational agents, our clinical and nonclinical plans, our plans to present or report
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |